Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company ...

Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes ...

A specially engineered antibody that can accurately deliver RNA treatments into hard-to-reach and hard-to-treat tumors ...

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits ...

A specially engineered antibody capable of delivering RNA therapies to hard-to-reach, treatment-resistant tumors ...

DelveInsight's, “Oncolytic Virus Cancer Therapy Pipeline Insight, 2025,” report provides comprehensive insights about 120+ ...

Cancer immunotherapy has transformed the treatment landscape by helping the immune system recognize and attack tumors. At the ...

KOL webinar to take place on July 22, 2025, at 1:00 p.m. ET SAN DIEGO and CALGARY, AB, July 10, 2025 /CNW/ — Oncolytics ...

Baystreet.ca News Commentary – With cancer cases rising and treatment costs hitting new highs, the private sector is under ...

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.